April 5, 2022Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
View Full Paper
Ask AI
Bookmark
Share
Key result
Stage III breast cancer is linked to ~22% higher circulating PCSK9 levels versus benign lesions.
- P=0.031
- n=46
Why the study?
Circulating levels of the targets of a new generation of lipid-lowering drugs, including PCSK9, ANGPTL3, and Lp(a), have not been fully investigated in cancers.
Do circulating levels of PCSK9, ANGPTL3, and Lp(a) differ in women with stage III breast cancer compared to women with premalignant or benign breast lesions?
Comparison
Stage III breast cancer vs premalignant (stage 0) or benign breast lesions
Design
Age-matched case-control study
Authors
Discussion
Loading...
Member takes
Implication
Higher PCSK9 may mark breast cancer severity; hypothesis-generating and should not yet change practice or prompt PCSK9 inhibitor trials.
Study Design
Type
Case-Control (n=46)
Multicenter
No
Structured PICO
Do circulating levels of PCSK9, ANGPTL3, and Lp(a) differ in women with stage III breast cancer compared to women with premalignant or benign breast lesions?
P
Population
46 women, including 23 with stage III breast cancer (ductal, lobular or mixed) and 23 age-matched controls with premalignant (stage 0, n=9) or benign (n=14) breast lesions.
C
Comparator
Age-matched women with premalignant (stage 0) or benign breast lesions.
O
Outcome
Circulating levels of PCSK9, ANGPTL3, and Lp(a)surrogate
Main Result
Absolute Event Rate: 95.9% vs 78.5%
p-value: p=0.031
Circulating PCSK9 levels are elevated in women with stage III breast cancer compared to those with benign breast lesions, suggesting a potential role of PCSK9 in breast cancer severity.
Limitations
- Limited amount of plasma samples (small sample size)
- Control group merged non-cancerous with early-stage cancerous samples
- Information on medications such as statins was unknown
- Ethnical origins of women were not documented
- Small sample size
Cite This Study
Chong et al. (2022) conducted a case-control in Breast cancer (n=46). Stage III breast cancer vs. Benign breast lesion was evaluated on Circulating PCSK9 levels (ng/mL) (p=0.031). Circulating PCSK9 levels were significantly higher in women with stage III breast cancer compared to age-matched counterparts presenting a benign breast lesion (95.9 vs 78.5 ng/mL).
View Full Paper
Ask AI
Bookmark
Share